Pular para o conteúdo

Conheça Walt Disney World

Corticotropin-releasing hormone receptor

corticotropin releasing hormone receptor 1
Image of Corticotropin-releasing hormone 1
Identifiers
SymbolCRHR1
Alt. symbolsCRHR
NCBI gene1394
HGNC2357
OMIM122561
RefSeqXM_001128344
UniProtP34998
Other data
LocusChr. 17 q12-q22
Search for
StructuresSwiss-model
DomainsInterPro
corticotropin releasing hormone receptor 2
Identifiers
SymbolCRHR2
NCBI gene1395
HGNC2358
OMIM602034
RefSeqNM_001883
UniProtQ13324
Other data
LocusChr. 7 p21-p15
Search for
StructuresSwiss-model
DomainsInterPro

Corticotropin-releasing hormone receptors (CRHRs), also known as corticotropin-releasing factor receptors (CRFRs), are a family of G protein-coupled receptors that bind corticotropin-releasing hormone (CRH).[1] There are two main subtypes in this receptor family, designated as type 1 and type 2, each encoded by a distinct gene—CRHR1 and CRHR2, respectively.

These receptors play a central role in regulating the hypothalamic-pituitary-adrenal (HPA) axis, a complex system that controls the release of stress-related hormones such as cortisol. The CRHR-mediated stress response is crucial for maintaining homeostasis, or physiological equilibrium. However, dysregulation of this system has been linked to several mental health disorders, including anxiety, depression, and post-traumatic stress disorder (PTSD).

Corticotropin-releasing hormone receptors are classified into two subtypes: CRHR1 and CRHR2. CRHR1 is primarily involved in initiating the stress response, whereas CRHR2 appears to modulate both the initiation and resolution of that response. Understanding how these receptors function within the HPA axis—and how their activity is influenced by genetic and environmental factors—is essential for developing treatments for stress-related disorders.[2]

Function

The hypothalamic-pituitary-adrenal (HPA) axis is a central neuroendocrine system that modulates the body's response to stress. It governs the release of hormones that prepare the body for immediate action—the “fight or flight” response—and subsequently restore physiological balance. At the core of this system is the release of corticotropin-releasing hormone (CRH) from the hypothalamus, which binds to corticotropin-releasing hormone receptors (CRHRs) in the anterior pituitary gland. This interaction stimulates the secretion of adrenocorticotropic hormone (ACTH), which acts on the adrenal glands to release cortisol.[3]

Cortisol increases blood glucose levels, improves cardiovascular output, and suppresses non-essential functions such as digestion and reproduction, enabling the body to respond effectively to stress. However, chronic elevation of cortisol may contribute to immune suppression, obesity, and cardiovascular disease.[3]

Signaling and feedback regulation

Receptor activation

CRH binds to two receptor subtypes—CRHR1 and CRHR2—which are G protein-coupled receptors (GPCRs) that activate different intracellular signaling pathways depending on ligand, tissue, and context. CRHR1 generally couples with Gαs proteins, triggering adenylyl cyclase, cAMP production, and activation of protein kinase A (PKA).[4]

CRHR2 also couples with G proteins but preferentially activates pathways involving phospholipase C, leading to hydrolysis of PIP2 into IP3 and DAG, which mobilize calcium and activate protein kinase C (PKC), respectively.[5]

Feedback mechanisms

The HPA axis uses negative feedback to regulate hormone levels. Elevated cortisol suppresses CRH and ACTH production, ensuring return to homeostasis.[6] Disruption of this loop can lead to sustained cortisol elevation, contributing to psychiatric disorders and metabolic diseases.[7]

Stress response

CRHR1: initiation

CRHR1 is highly expressed in stress-responsive brain regions such as the hypothalamus, amygdala, and hippocampus. Upon activation by CRH, it triggers ACTH release through hypothalamic-pituitary-adrenal (HPA) axis activation and initiates the physiological stress response.[8] CRHR1 activation enhances neuronal excitability in the hippocampus by modulating potassium channels (KV1 subfamily), increasing population spike amplitudes through presynaptic mechanisms.[9]

In the amygdala, CRHR1 enhances fear and anxiety through Gsα-coupled signaling pathways that increase cAMP production and CREB phosphorylation.[10] Hippocampal CRHR1 activation impairs memory and learning by reducing long-term potentiation through calcineurin-mediated suppression of potassium currents (IA and IK).[9][11]

Dysregulation of CRHR1 contributes to anxiety, depression, PTSD, and cognitive impairment. Chronic CRHR1 activation leads to HPA axis hyperactivity and reduced hippocampal neurogenesis.[12] Genetic studies show specific CRHR1 variants (rs12938031, rs4792887) increase PTSD risk after trauma exposure through impaired cortisol feedback.[13] Preclinical models demonstrate CRHR1 antagonists reverse stress-induced dendritic atrophy in prefrontal cortex pyramidal neurons.[14]

CRHR2: termination

CRHR2 expression is more restricted but includes the ventromedial hypothalamus, bed nucleus of stria terminalis, and peripheral tissues. It serves to attenuate the stress response through urocortin 3 binding, which activates Gq-coupled pathways that suppress CRH release and enhance negative feedback.[15] CRHR2 activation increases brain-derived neurotrophic factor (BDNF) expression in the ventral tegmental area, promoting stress resilience.[14]

CRHR2 dysfunction impairs HPA axis recovery, contributing to prolonged stress responses and emotional dysregulation. Knockout models show 40% increased anxiety-like behaviors in elevated plus maze tests and delayed cortisol normalization after restraint stress.[15] Human studies link CRHR2 polymorphisms to altered startle response habituation and impaired fear extinction in PTSD patients.[16] The receptor's peripheral effects include modulation of cardiovascular tone through ERK1/2-dependent pathways in vascular smooth muscle cells.[17][18]

Mechanisms of signaling

Both CRHR1 and CRHR2 activate intracellular cascades involving cAMP/PKA or IP3/DAG signaling. These influence gene expression, including activation of CREB, a transcription factor that upregulates genes related to plasticity, stress response, and immunity. Sustained CRHR activation can create a feedback loop of increased CRH expression, contributing to receptor desensitization and maladaptive stress responses.[4]

Genetic variants and stress susceptibility

Polymorphisms in CRHR1 and CRHR2 genes influence receptor function and stress vulnerability. CRHR1 SNPs have been linked to increased risk of anxiety and depression, especially in individuals exposed to early-life stress.[19]

Variants in CRHR2 are associated with better stress recovery and reduced PTSD risk, likely due to improved feedback regulation of cortisol.[20]

Clinical relevance and therapeutics

CRHR1 antagonists

Antagonists targeting CRHR1 have shown promise in reducing anxiety, depression, and PTSD symptoms by limiting cortisol release and dampening stress-related signaling. For example, Verucerfont (GSK561679), a selective CRHR1 antagonist, has been evaluated of treating PTSD symptoms in a Phase II randomized controlled trial involving women with chronic PTSD.[21] The CRHR1 antagonist antalarmin has been shown in animal studies to protect against stress-induced colonic injury by reducing NF-κB-mediated inflammation and stabilizing gut microbiota.[22]

NBI30775 (R121919), which reversed synaptic loss in hippocampal CA1/CA3 regions and rescued trauma-induced memory deficits in aged mice.[23] Mechanistically, CRHR1 antagonists suppress Gαs-cAMP-PKA signaling cascades, normalizing HPA axis hyperactivity and dendritic atrophy in prefrontal cortex neurons.[24]

CRHR2 modulators

Drugs targeting CRHR2 aim to enhance feedback mechanisms and restore balance in the HPA axis. The orally bioavailable CRHR2 antagonist RQ-00490721 attenuated pressure overload-induced cardiac dysfunction in mice by suppressing CREB/AKT phosphorylation pathways, highlighting its potential for heart failure treatment.[25] CRHR2 activation via urocortin 2 promotes stress resilience by increasing BDNF expression in the ventral tegmental area and facilitating fear extinction.[26]

Genetic studies reveal that CRHR2 knockout models exhibit increased anxiety-like behaviors and impaired cortisol normalization post-stress.[27] Emerging modulators aim to exploit CRHR2's role in peripheral tissues-for example, its ERK1/2-dependent regulation of vascular smooth muscle tone-to address stress-related cardiovascular comorbidities.[28]

References

  1. ^ Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM (Mar 2003). "International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands". Pharmacological Reviews. 55 (1): 21–26. doi:10.1124/pr.55.1.3. PMID 12615952. S2CID 1572317.
  2. ^ Sukhareva EV (2021-04-29). "The role of the corticotropin-releasing hormone and its receptors in the regulation of stress response". Vavilovskii Zhurnal Genetiki I Selektsii. 25 (2): 216–223. doi:10.18699/VJ21.025. ISSN 2500-3259. PMC 8627883. PMID 34901719.
  3. ^ a b "Hypothalamic-Pituitary-Adrenal (HPA) Axis". Cleveland Clinic. April 12, 2024. Retrieved March 8, 2025.
  4. ^ a b Inda C, Armando NG, Claro PA, Silberstein S (August 2017). "Endocrinology and the brain: corticotropin-releasing hormone signaling". Endocrine Connections. 6 (6): R99 – R120. doi:10.1530/EC-17-0111. ISSN 2049-3614. PMC 5551434. PMID 28710078.
  5. ^ "GPCR | Learn Science at Scitable". www.nature.com. Retrieved 2025-03-09.
  6. ^ Henley C (2021-01-01). "HPA Axis". Foundations of Neuroscience.
  7. ^ Raise-Abdullahi P, Meamar M, Vafaei AA, Alizadeh M, Dadkhah M, Shafia S, et al. (June 23, 2023). "Hypothalamus and Post-Traumatic Stress Disorder: A Review". Brain Sciences. 13 (7): 1010. doi:10.3390/brainsci13071010. PMC 10377115. PMID 37508942.
  8. ^ Chinnathambi S, Chidambaram H (2020-07-01). "G-Protein Coupled Receptors and Tau-different Roles in Alzheimer's Disease". Neuroscience. 438: 198–214. doi:10.1016/j.neuroscience.2020.04.019. ISSN 0306-4522. PMID 32335218.
  9. ^ a b Refojo D, Schweizer M, Kuehne C, Ehrenberg S, Thoeringer C, Wolf AM, et al. (2011-09-30). "Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1". Science. 333 (6051). New York, N.Y.: 1871–1874. Bibcode:2011Sci...333.1903R. doi:10.1126/science.1202107. PMID 21960631.
  10. ^ Hubbard DT, Nakashima BR, Lee I, Takahashi LK (2007-12-19). "Activation of basolateral amygdala corticotropin-releasing factor 1 receptors modulates the consolidation of contextual fear". Neuroscience. 150 (4): 818–828. doi:10.1016/j.neuroscience.2007.10.001. PMC 2174904. PMID 17988803.
  11. ^ Blank T, Nijholt I, Eckart K, Spiess J (2002-05-01). "Priming of long-term potentiation in mouse hippocampus by corticotropin-releasing factor and acute stress: implications for hippocampus-dependent learning". The Journal of Neuroscience. 22 (9): 3776–3787. doi:10.1523/JNEUROSCI.22-09-03788.2002. PMC 6758446. PMID 11978853.
  12. ^ Goparaju P, Postolache TT, del Bosque-Plata L, Gragnoli C, Perrelli M (June 2024). "Stress and the CRH System, Norepinephrine, Depression, and Type 2 Diabetes". Biomedicines. 12 (6): 1187. doi:10.3390/biomedicines12061187. PMC 11200886. PMID 38927393.
  13. ^ Acierno R, Ruggiero KJ, Koenen KC, Kilpatrick DG, Galea S, Gelernter J, et al. (2013-10-01). "Association of CRHR1 variants and posttraumatic stress symptoms in hurricane exposed adults". Journal of Anxiety Disorders. 27 (7): 678–683. doi:10.1016/j.janxdis.2013.08.003. ISSN 0887-6185. PMC 4182958. PMID 24077033.
  14. ^ a b Sagar GD, Gereben B, Callebaut I, Mornon JP, Zeöld A, Curcio-Morelli C, et al. (2008-06-01). "Central Nervous System-Specific Knockout of Steroidogenic Factor 1". Molecular Endocrinology. 22 (6). Baltimore, Md.: 1382–1393. doi:10.1210/me.2007-0490. PMC 2422836. PMID 18356288.
  15. ^ a b Inda C, Bonfiglio JJ, dos Santos Claro PA, Senin SA, Armando NG, Deussing JM, et al. (2017-05-15). "cAMP-dependent cell differentiation triggered by activated CRHR1 in hippocampal neuronal cells". The American Journal of Case Reports. 18 (1): 537–540. Bibcode:2017NatSR...7.1944I. doi:10.1038/s41598-017-02134-z. PMC 5431483. PMID 28507284.
  16. ^ Kishimoto T, Radulovic J, Radulovic M, Lin CR, Schrick C, Hooshmand F, et al. (2000-04-01). "Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2". Nature Genetics. 24 (4): 415–419. doi:10.1038/74271. PMID 10742109.
  17. ^ Parra-Mercado GK, Fuentes-Gonzalez AM, Hernandez-Aranda J, Diaz-Coranguez M, Dautzenberg FM, Catt KJ, et al. (2019). "CRF1 Receptor Signaling via the ERK1/2-MAP and Akt Kinase Cascades: Roles of Src, EGF Receptor, and PI3-Kinase Mechanisms". Frontiers in Endocrinology. 10: 869. doi:10.3389/fendo.2019.00869. PMC 6921279. PMID 31920979.
  18. ^ Walczewska J, Dzieza-Grudnik A, Siga O, Grodzicki T (December 2014). "The role of urocortins in the cardiovascular system". Journal of Physiology and Pharmacology. 65 (6): 753–766. PMID 25554979.
  19. ^ Smoller JW (August 31, 2015). "The Genetics of Stress-Related Disorders: PTSD, Depression, and Anxiety Disorders". Neuropsychopharmacology. 41 (1): 297–319. doi:10.1038/npp.2015.266. ISSN 1740-634X. PMC 4677147. PMID 26321314.
  20. ^ Wolf EJ, Mitchell KS, Logue MW, Baldwin CT, Reardon AF, Humphries DE, et al. (December 1, 2014). "The Corticotropin Releasing Hormone Receptor 2 (CRHR-2) Gene is Associated with Decreased Risk and Severity of Posttraumatic Stress Disorder in Women". Depression and Anxiety. 30 (12): 1161–1169. doi:10.1002/da.22176. PMC 3855198. PMID 24123648.
  21. ^ Rothbaum BO, Binder EB, Duncan E, Harvey PD, Jovanovic T, Kelley ME, et al. (2014-06-21). "Evaluation of a corticotropin releasing hormone type 1 receptor antagonist in women with posttraumatic stress disorder". Trials. 15 (1): 240. doi:10.1186/1745-6215-15-240. PMC 4082482. PMID 24950747.
  22. ^ Larauche M, Kiank C, Tache Y (December 2009). "Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications". Journal of Physiology and Pharmacology. 60 (Suppl 7): 33–46. PMID 20388953.
  23. ^ Wang X, Li G, Liu Y, Liu Y, Wang Y, Wang Y, et al. (2020-04-28). "CRHR1 antagonist reverses synaptic loss and cognitive deficits induced by chronic stress in aged mice". Frontiers in Aging Neuroscience. 12: 245. doi:10.3389/fnagi.2020.00245. PMC 7201786. PMID 32410909.
  24. ^ Qiu L, Zhang H, Zhou Z, Ju L, Yang J, Sun J (2023-01-09). "CRHR1 antagonist alleviates LPS-induced depression-like behaviour in mice". BMC Psychiatry. 23 (1): 17. doi:10.1186/s12888-023-04519-z. PMC 9830857. PMID 36624454.
  25. ^ Yamamoto T, Saito Y, Nakayama K, Sato T, Nakamura T, Yamada T, et al. (2021-11-15). "A novel, orally available corticotropin-releasing hormone receptor type 2-selective antagonist, RQ-00490721, attenuates pressure overload-induced cardiac dysfunction in mice". European Journal of Pharmacology. 911 (7): 174487. doi:10.1016/j.ejphar.2021.174487. PMC 9372922. PMID 34517258.
  26. ^ Kormos V, Gaszner B, Kovács KJ (2016-09-13). "Role of CRH in neural plasticity and stress-induced pathology". Frontiers in Endocrinology. 7: 123. doi:10.3389/fendo.2016.00123. PMC 5027273. PMID 27679536.
  27. ^ Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, et al. (April 2000). "Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress". Nature Genetics. 24 (4): 410–414. doi:10.1038/74271. PMID 10742109.
  28. ^ Kageyama K, Suda T (2019-03-28). "Regulatory mechanisms underlying corticotropin-releasing factor receptor expression in the hypothalamus". Endocrine Journal. 66 (3): 227–234. doi:10.1507/endocrj.EJ18-0441. PMID 30700619.
fonte: https://en.wikipedia.org/wiki/Corticotropin-releasing_hormone_receptor
Marcações: